Analysis of Clinical Distribution and Drug Resistance of Acinetobacter baumannii in a Third-grade Class-A Hospital from Chongqing during 2015 to 2018
- VernacularTitle:2015－2018年重庆市某三级甲等医院鲍曼不动杆菌的临床分布及耐药性分析
- Author:
Lirong XIONG
1
;
Wei FENG
1
;
Rongfeng XIANG
1
;
Mingjie YU
1
;
Qing DAI
1
;
Yongchuan CHEN
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Army Medical University，Chongqing 400038，China
- Publication Type:Journal Article
- Keywords:
Acinetobacter baumannii;
Clinical distribution;
Antibiotics;
Drug resistance;
Chongqing
- From:
China Pharmacy
2020;31(3):340-343
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To provide reference for clinical treatment of Acinetobacter baumannii infection and rational use of antibiotics. METHODS ：By retrospective analysis ，64 500 strains of bacteria were isolated from the inpatients of our hospital during Jan. 2015 to Dec. 2018. WHONET 5.6 software was used to analyze the detection rate ，specimen type ，departments of A. baumannii. The resistance of A. baumannii to 18 commonly used antibiotics in 4 years was analyzed by RxC table χ 2 test. RESULTS：A total of 2 072，2 040，2 017 and 2 143 strains of A. baumannii were isolated during 2015-2018，accounting for 12.85％，13.38％，13.60％，11.71％ of positive specimens. The main specimen types of 8 272 strains of A. baumannii were sputum（4 368 strains，52.81％），pus（1 106 strains，13.37％），ascites（804 strains，9.72％）. The main departments were burn department（1 605 strains，19.40％），hepatobiliary department （1 200 strains，14.51％），brain surgery department （977 strains， 11.81％）. The drug resistance rate to 18 kinds of antibiotics showed a wave-like decreasing trend （P＜0.001）. In 2018，drug resistance rate to ampicillin and aztreonam was more than 80％，and that to ampicillin/sulbactam ，ceftazidime，levofloxacin， Compound sulfamethoxazole ，gentamicin，amikacin，tobramycin and tegacyclin was less than 50％ ，among which the drug resistance rate to amikacin and tegacyclin were 14.7％ and 0，respectively. CONCLUSIONS ：There is no significant change in the number of isolates and detection rate of A. baumannii in our hospital between 2015 and 2018. The bacteria mainly cause respiratory tract infection. Amikacin or tegacyclin are recommended for treatment.
